Page 84 - 2021_10-Haematologica-web

P. Giannoni et al.
35. Mangolini M, Ringshausen I. Bone marrow stromal cells drive key hallmarks of B cell malignancies. Int J Mol Sci. 2020;21(4):1466.
36. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986;319(6053):516-518.
37. Nanes MS. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skele- tal pathology. Gene. 2003;321:1-15.
38. Foa R, Massaia M, Cardona S, et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood. 1990;76 (2):393-400.
39. Ferrajoli A, Keating MJ, Manshouri T, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood. 2002;100(4):1215-1219.
40. Colucci S, Brunetti G, Cantatore FP, et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model
derived from human psoriatic arthritis. J
Pathol. 2007;212(1):47-55.
41. Dimitroulas T, Nikas SN, Trontzas P, Kitas
GD. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev. 2013;12(10):958-966.
42. Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis fac- tor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets. 2008;12(9):1085- 1096.
43. LuoG,LiF,LiX,WangZG,ZhangB. TNFalpha and RANKL promote osteoclasto- genesis by upregulating RANK via the NFkappaB pathway. Mol Med Rep. 2018;17(5):6605-6611.
44. McCoy EM, Hong H, Pruitt HC, Feng X. IL- 11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells. BMC Cancer. 2013;13:16.
45.Kim MS, Day CJ, Selinger CI, Magno CL, Stephens SR, Morrison NA. MCP-1-induced human osteoclast-like cells are tartrate-resis- tant acid phosphatase, NFATc1, and calci- tonin receptor-positive but require receptor
activator of NFkappaB ligand for bone resorp-
tion. J Biol Chem. 2006;281(2):1274-1285. 46. Amarasekara DS, Yun H, Kim S, Lee N, Kim H, Rho J. Regulation of osteoclast differenti- ation by cytokine networks. Immune Netw.
2018;18(1):e8.
47. Marcelli C, Chappard D, Rossi JF, et al.
Histologic evidence of an abnormal bone remodeling in B-cell malignancies other than multiple myeloma. Cancer. 1988;62(6):1163- 1170.
48. Chappard D, Rossi JF, Bataillle R, Alexandre C. Osteoclast cytomorphometry and scan- ning electron microscopy of bone eroded surfaces during leukemic disorders. Scanning Microsc. 1990;4(2):323-328.
49. Chappard D, Rossi JF, Bataille R, Alexandre C. Osteoclast cytomorphometry demon- strates an abnormal population in B cell malignancies but not in multiple myeloma. Calcif Tissue Int. 1991;48(1):13-17.
50.Rossi JF, Chappard D, Marcelli C, et al. Micro-osteoclast resorption as a characteris- tic feature of B-cell malignancies other than multiple myeloma. Br J Haematol. 1990;76 (4):469-475.
2612
haematologica | 2021; 106(10)